Skip to Content

Dinoprostone Topical Dosage

Applies to the following strength(s): 0.5 mg/3 g ; 20 mg ; 10 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Labor Induction

VAGINAL INSERT:
-The dosage of the vaginal insert is 10 mg designed to be released at approximately 0.3 mg/hour over a 12-hour period; the insert should be removed upon onset of active labor or 12 hours after insertion
-The manufacturer product information should be consulted for instructions relating to product preparation and proper insertion.
-Care should be taken to ensure the vaginal insert remains in place if the patient is ambulatory.
-Upon removal of the insert, it is essential to ensure that the slab has been removed, as it will continue delivering the active ingredient. The knitted polyester retrieval system should be visualized to confirm that it contains the slab. If the slab is not contained within the polyester retrieval system, a vaginal exam is recommended to remove the slab.

CERVICAL GEL:
-Vaginal examination will reveal the degree of effacement which will regulate the size of the shielded endocervical catheter to be used. The 20 mm endocervical catheter should be used if no effacement is present, and the 10 mm catheter should be used if the cervix is 50% effaced. The cervical gel should not be administered above the level of the internal os.
-This product should be handled carefully to prevent contact with skin. Hands should be washed thoroughly with soap and water after administration.
-The manufacturer product information should be consulted for instructions relating to product preparation and proper insertion.
-Following administration the patient should remain in the supine position for at least 15 to 30 minutes to minimize leakage from the cervical canal.
-If the desired response is obtained, the recommended interval before giving IV oxytocin is 6 to 12 hours.
-If there is no cervical/uterine response to the initial dose of the cervical gel, repeat dosing may be given. The recommended repeat dose is 0.5 mg with a dosing interval of 6 hours.
-The need for additional dosing and the interval should be determined by the attending physician based on the course of clinical events.
-The maximum recommended cumulative dose for a 24-hour period is 1.5 mg of this drug.

Use: For ripening an unfavorable cervix in pregnant women at or near term with a medical or obstetrical need for labor induction

Usual Adult Dose for Abortion

VAGINAL SUPPOSITORY:
-A 20 mg suppository should be inserted high into the vagina; the patient should remain in the supine position for 10 minutes following insertion
-Additional intravaginal administration of each subsequent suppository should be at 3 to 5 hour intervals until abortion occurs. Within the recommended intervals administration time should be determined by abortifacient progress, uterine contractility response, and by patient tolerance.
-Continuous administration for more than 2 days is not recommended.
-The manufacturer product information should be consulted for instructions relating to product preparation and proper administration.

Uses:
-For the termination of pregnancy from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period
-For evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period
-For the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole)

Usual Adult Dose for Trophoblastic Disease

VAGINAL SUPPOSITORY:
-A 20 mg suppository should be inserted high into the vagina; the patient should remain in the supine position for 10 minutes following insertion
-Additional intravaginal administration of each subsequent suppository should be at 3 to 5 hour intervals until abortion occurs. Within the recommended intervals administration time should be determined by abortifacient progress, uterine contractility response, and by patient tolerance.
-Continuous administration for more than 2 days is not recommended.
-The manufacturer product information should be consulted for instructions relating to product preparation and proper administration.

Uses:
-For the termination of pregnancy from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period
-For evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period
-For the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole)

Renal Dose Adjustments

Vaginal insert: Data not available
Cervical gel: Caution recommended
Vaginal suppository: Contraindicated

Liver Dose Adjustments

Vaginal insert: Data not available
Cervical gel: Caution recommended
Vaginal suppository: Contraindicated

Precautions

US BOXED WARNINGS:
Vaginal Suppository:
-This drug, as with other potent oxytocic agents, should be used only with strict adherence to recommended dosages.
-This drug should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.

This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Consult the manufacturer product information.

Storage requirements:
-Consult the manufacturer product information.

Reconstitution/preparation techniques:
-Consult the manufacturer product information.

Hide